Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma-Reference-Cited by-同舟云学术

Mechanism and Treatment of Rituximab Resistance in Diffuse Large Bcell Lymphoma

Published:2019-12-20 Issue:9 Volume:19 Page:681-687
ISSN:1568-0096
Container-title:Current Cancer Drug Targets
language:en
Short-container-title:CCDT

Author:

Zou Linqing¹,Song Guoqi²,Gu Siyu¹,Kong Lingling¹,Sun Shiqi¹,Yang Li¹,Cho William C.³

Affiliation:

1. Department of Medicine, Nantong University, Nantong, Jiangsu 226001, China

2. Department of Hematology, Affiliated Hospital of Nantong University, Nantong, China

3. Department of Clinical Oncology, Queen Elizabeth Hospital, Kowloon, Hong Kong

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype B non-Hodgkin lymphoma in adults. After rituximab being introduced to treat DLBCL, the current first-line treatment is R-CHOP regimen. This regimen greatly improves patient's prognosis, however, relapsed or refractory cases are commonly seen, mainly due to the resistance to rituximab. Although a large number of experiments have been conducted to investigate rituximab resistance, the exac mechanisms and solutions are still unclear. This review mainly explores the possible mechanisms oft rituximab resistance and current new effective treatments for rituximab resistance in DLBCL.

Funder

National Nature Science Foundation of China

Publisher

Bentham Science Publishers Ltd.

Subject

Cancer Research,Drug Discovery,Pharmacology,Oncology

Reference68 articles.

1. Martelli M.; Ferreri A.J.; Agostinelli C.; Di Rocco A.; Pfreundschuh M.; Pileri S.A.; Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol 2013,87(2),146-171

2. Schneider C.; Pasqualucci L.; Dalla-Favera R.; Molecular pathogenesis of diffuse large B-cell lymphoma. Semin Diagn Pathol 2011,28(2),167-177

3. Shaffer A.L.; Young R.M.; Staudt L.M.; Pathogenesis of human B cell lymphomas. Annu Rev Immunol 2012,30,565-610

4. Nastoupil L.J.; Rose A.C.; Flowers C.R.; Diffuse large B-cell lymphoma: current treatment approaches. Oncology (Williston Park) 2012,26(5),488-495

5. Tedder T.F.; Disteche C.M.; Louie E.; Adler D.A.; Croce C.M.; Schlossman S.F.; Saito H.; The gene that encodes the human CD20 (B1) differentiation antigen is located on chromosome 11 near the t(11;14)(q13;q32) translocation site. J Immunol 1989,142(7),2555-2559

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Two cases on primary bone marrow lymphoma;Cancer Pathogenesis and Therapy;2024-01

2. Therapeutic options for rituximab-resistant patients;Resistance to Anti-Cd20 Antibodies and Approaches for their Reversal;2024

3. Radio-immunotherapy by 188Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphoma;Gene;2023-10

4. Effect of a CrossMab cotargeting CD20 and HLA-DR in non-Hodgkin lymphoma;Oncologie;2023-07-20

5. A novel prednisone premedication protocol significantly decreases infusion‑related reactions of rituximab in newly diagnosed diffuse large B‑cell lymphoma;Oncology Letters;2023-04-28